Article: Research Update.

 
 New Long-Term Safety and Efficacy Data On EXUBERA(R) (Human Insulin Powder) 
Presented at American Diabetes Association Scientific Sessions 
 
ORLANDO, Fla., June 7 -- Results of long-term studies showed sustained 
glycemic control and pulmonary function in patients with type 2 diabetes taking 
EXUBERA(R), an inhalable, rapid-acting dry powder insulin.(1,2)  These new data 
were presented this weekend at the 64th Annual Scientific Sessions of the 
American Diabetes Association. 
A pooled analysis of two one-year open-label studies involving 627 
patients with type 2 diabetes showed that patients who added EXUBERA(R) to 
their treatment regimen experienced no ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!